ArticleRadiation oncology (London, England)2026
Stereotactic radiosurgery for brain metastases: multistate and competing risk models of progression and survival from a single-centre 11-year experience.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stereotactic radiosurgery for brain metastases from male breast cancer: a multicenter retrospective study.Journal of neuro-oncology · 2026Article
- A novel strategy for soft tissue sarcoma lattice radiotherapy: integrating X-ray andγ-ray technologies to optimize dose delivery.Radiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of brain metastases has risen due to advances in systemic treatments prolonging survival and the use of MRI. Whilst surgical resection remains a valuable mean of acutely alleviating raised intracranial pressure, reducing seizure risk, and preventing progression of neurological deficit, stereotactic radiosurgery (SRS) delivers radiotherapy to precise target volumes, including the treatment of a larger number of metastases with high rates of local control, whilst avoiding the neurological complications of WBRT or the need for invasive resection. The aim of this study was to evaluate the 11-year experience of SRS at the Leeds Gamma Knife Centre, examining patient outcomes, and the association of patient-dependent factors and intracranial disease burden to survival.
methodsA retrospective cohort study of 1,031 patients (2,836 metastases) treated with SRS at the Leeds Gamma Knife Centre between 2010 and 2020. Data included primary tumour, Karnofsky performance status, intracranial disease burden, and prior/subsequent treatment. Follow-up was at least 30 months. Kaplan-Meier analysis was used for 10-year survival curves. Multistate and competing risks models assessed progression/death predictors.
resultsLung (50.4%), breast (15.4%) and melanoma (9.9%) were the most common primary tumour. 364 (35.3%) patients had recurrence, and 875 (84.5%) died by the end of follow-up. Survival outcomes were worse in men compared to women in both lung (p = 0.003) and other (p = 0.02) metastases. Breast cancer patients spent the most time in the no progression state (rmean = 1.56 years) whereas gastrointestinal primary spent the least (rmean = 0.99 years). Each additional metastatic lesion at the time of treatment increased the risk of progression by 9.2% (p < 0.001), but risk of death was not influenced by the number of lesions (p = 0.30); conversely, total tumour volume increased the risk of death by 2.2% for each 1cm3 increase. Post-SRS new metastatic disease increased the risk of death by 31% (p = 0.02), whilst local recurrence did not (p = 0.26).
conclusionThese findings add to the accepted prognostic factors for brain metastases, further informing clinical consultations with patients, but further research is required to address unanswered questions regarding the role of SRS in relation to other treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.